Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06692972

The Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy

Exploration of and Model Establishment of the Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy

Status
Recruiting
Phase
Study type
Observational
Enrollment
500 (estimated)
Sponsor
China-Japan Friendship Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Definitive radiotherapy is one of the important methods for inoperable locally advanced lung cancer. The recommended dose for definitive radiotherapy is 60-70Gy, and the optimal dose is still uncertain. Residual lesion after radiotherapy is a risk factor for recurrence. High doses to targeted tumor areas can effectively improve the local control rate, while minimizing toxic side effects. The regression pattern of primary lesions in lung caner after radiotherapy has not been clarified. This study intends to retrospectively collect clinical data of lung cancer patients with definitive radiotherapy, and explore the pattern of tumor regression after radiotherapy. It will help optimize the radiotherapy plan for lung cancer, so as to improve the efficacy and prognosis.

Detailed description

This study intends to retrospectively screen and include participants according to inclusion and exclusion criteria, and collect the clinical data of participants by previous medical records. Imaging tools will be used to quantify changes in the spatial location, diameter and volume of target lesions to evaluate tumor regression rate and radiotherapy efficacy, and to explore tumor regression pattern and establish model. In addition, the relationship between tumor regression rate, incidence of adverse radiation events, prognosis and related factors will be analysed.

Conditions

Timeline

Start date
2024-12-25
Primary completion
2025-04-30
Completion
2025-12-31
First posted
2024-11-18
Last updated
2025-02-27

Locations

2 sites across 1 country: China

Source: ClinicalTrials.gov record NCT06692972. Inclusion in this directory is not an endorsement.